Mild traumatic brain injury arrives without fanfare. The initial impact fades, yet the secondary injury unfolds over days, reshaping neurons and behavior alike. A new study published online on 16 July 2026 in Experimental Neurology demonstrates that intranasal ketamine, delivered for one week after injury, can blunt that cascade in a mouse model.

The work, led by Mohd Aleem, Princy Verma, Harshita Sharma, Sunidhi Bisht, Ananya Madan and Kailash Manda, tested low-dose intranasal ketamine in C57BL/6 mice subjected to mild lateral fluid percussion injury. Neurological severity scores improved more rapidly in treated animals. Anxiety- and depression-like behaviors diminished. Cognitive performance and neuromuscular function recovered better. Dendritic architecture held steadier under Golgi-Cox staining, and fewer neurons died in cortex and hypothalamus. Neuroinflammation eased in cortex and hippocampal subfields.

The quiet mechanics of secondary damage

Mild traumatic brain injury, often abbreviated mTBI, triggers depolarization that spreads across cortex as cortical spreading depolarization. Calcium floods cells. NMDA receptors, already overstimulated, amplify the imbalance. The result is swelling, distorted dendrites, microvascular harm and, later, inflammation that erodes function even when the initial blow was modest.

Fluid percussion injury replicates this sequence in controlled laboratory settings. A brief saline pulse through a cranial window mimics the biomechanical forces of concussion without gross tissue destruction. In the present experiments the injury remained mild by design, yet measurable deficits emerged in behavior and histology.

Why the nose rather than the vein

Intranasal administration bypasses the blood-brain barrier through the olfactory and trigeminal pathways. Ketamine reaches central targets rapidly and at lower systemic doses. The seven-day regimen used here kept exposure minimal while sustaining effect during the window when secondary injury peaks.

The choice matters. Intravenous or intraperitoneal routes can produce unwanted locomotor or dissociative effects. Nasal delivery appears to concentrate action where it is needed most.

Behavioral recovery measured in layers

Neurological severity scores, a composite of reflexes and motor tasks, normalized faster under treatment. Open-field and elevated-plus-maze tests showed reduced anxiety-like avoidance. Forced-swim and sucrose-preference paradigms indicated relief from depression-like anhedonia. Novel-object recognition and spatial tasks reflected clearer cognitive gains. Rotarod and grip-strength measures confirmed better coordination and muscle power.

These outcomes did not appear in isolation. They tracked with preserved neuronal morphology: longer dendrites, richer arborization, higher spine density. Dead-cell counts fell significantly in key regions. Microglial activation and cytokine signals declined.

Photo by Pharmacy Images on Unsplash

One molecule, many downstream effects

Ketamine blocks NMDA receptors. By limiting calcium influx it may shorten spreading depolarization events and curb excitotoxic spread. Reduced inflammation follows, perhaps because fewer dying neurons release danger signals. Dendritic stability suggests the drug also protects cytoskeletal integrity during the vulnerable post-injury period.

The study does not claim a single mechanism. It shows convergent benefits across behavior, morphology and inflammation after a clinically relevant delivery route and duration.

Placing the finding in laboratory context

Fluid percussion models have served neurotrauma research for decades. They allow precise control of injury severity while reproducing the secondary injury sequence seen in human concussion. The present work adds intranasal ketamine to a growing list of interventions tested in this system, yet distinguishes itself by the route, the low dose and the breadth of endpoints examined.

Earlier preclinical work with ketamine after traumatic brain injury has explored intravenous infusions and different timing windows. The nasal approach here aligns with practical considerations for repeated dosing in awake subjects.

Implications for the research community

Translational neuroscience depends on reproducible models and clear outcome measures. This publication supplies both. Laboratories studying mTBI now have a defined protocol for intranasal ketamine that can be replicated or extended to other species or injury severities.

Funding bodies and institutional review boards will note the absence of overt adverse effects at the doses used. That safety signal, even if preliminary, lowers the barrier for follow-on studies.

From mouse to clinic: the translation gap

Mouse recovery does not equal human recovery. Species differences in nasal anatomy, drug metabolism and injury heterogeneity remain. Yet the behavioral domains tested map onto complaints common after human concussion: anxiety, low mood, memory lapses and balance problems. The histological correlates supply mechanistic plausibility.

Next steps will likely include dose-ranging in larger animals, pharmacokinetic mapping in humans and, eventually, controlled trials in patients with recent mTBI. Biomarker panels that track spreading depolarization or microglial activation could serve as intermediate endpoints.

Photo by Dennis Klicker on Unsplash

The archive of injury and its interpreters

Every new paper enters an existing record of what is known about brain recovery. The value lies less in any single result than in the cumulative capacity to read that record accurately. Intranasal ketamine now occupies a precise entry: it attenuates neuronal damage and behavioral deficits after mild fluid percussion injury when given for one week via the nasal route in this model.

The question that follows is not whether protection is possible, but which laboratories will next test the boundary conditions and which clinicians will decide whether the boundary has reached the bedside.

The original publication is available at https://www.sciencedirect.com/science/article/abs/pii/S0014488626002979. Further details on Experimental Neurology appear on the journal site.